Trial: 201605141

ARST1431 – A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)



Principal Investigator

Huang, Frederick

Disease Site

Anus; Cervix; Colon; Esophagus; Ill-Defined Sites; Kidney; Liver; Lung; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Pediatric Cancers; Rectum

Learn more about this study at: